Literature DB >> 16763015

Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts.

M Teresa Donato1, Agustín Lahoz, Nuria Jiménez, Gabriela Pérez, Alfonso Serralta, José Mir, José V Castell, M José Gómez-Lechón.   

Abstract

Liver grafts discarded for transplantation because of macrosteatosis can constitute a valuable source of human hepatocytes for in vitro metabolic and pharmacotoxicological studies or for therapeutic applications. A condition for using hepatocyte suspensions for these purposes is the preservation of their metabolic competence and, particularly, drug-metabolizing enzymes. A reduction in microsomal cytochrome P450 (P450) activities was observed in fatty livers (>40% steatosis) with respect to normal tissue. Similarly, decreased levels of 7-ethoxycoumarin O-deethylation and testosterone metabolism were observed in human hepatocyte cultures prepared from steatotic liver tissue. To clarify the potential impact of lipid accumulation on human hepatic P450 enzymes, we have used an in vitro model of "cellular steatosis" by incubation of cultured hepatocytes with increasing concentrations (0.25-3 mM) of long-chain free fatty acids (FFA). A dose-dependent accumulation of lipids in the cytosol is induced by FFA mixture. Hepatocytes exposed to 1 mM FFA for 14 h showed lower activity values of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP2E1, and CYP3A4 enzymes than nontreated hepatocytes (about 45-65% reduction). This treatment also produced significant decreases in CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP2E1, and CYP3A4 mRNA to about 55 to 75% of mRNA levels in control cells. Our results suggest that although human hepatocytes isolated from steatotic liver show reduced P450 activities, they are metabolically competent and can be used for drug metabolism studies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16763015     DOI: 10.1124/dmd.106.009670

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  34 in total

1.  A novel 3D liver organoid system for elucidation of hepatic glucose metabolism.

Authors:  Yanhua Lu; Guoliang Zhang; Chong Shen; Korkut Uygun; Martin L Yarmush; Qin Meng
Journal:  Biotechnol Bioeng       Date:  2011-10-19       Impact factor: 4.530

2.  Homogeneous phenomenon of the graft when using different genotype characteristic of recipients/donors in living donor liver transplantation.

Authors:  King-Wah Chiu; Toshiaki Nakano; Kuang-Den Chen; Li-Wen Hsu; Chia-Yun Lai; Ho-Ching Chiu; Ching-Yin Huang; Yu-Fan Cheng; Shigeru Goto; Chao-Long Chen
Journal:  World J Hepatol       Date:  2013-11-27

3.  Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver.

Authors:  Rohitash Jamwal; Suzanne M de la Monte; Ken Ogasawara; Sravani Adusumalli; Benjamin B Barlock; Fatemeh Akhlaghi
Journal:  Mol Pharm       Date:  2018-06-11       Impact factor: 4.939

Review 4.  Impact of obesity on drug metabolism and elimination in adults and children.

Authors:  Margreke J E Brill; Jeroen Diepstraten; Anne van Rongen; Simone van Kralingen; John N van den Anker; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2012-05-01       Impact factor: 6.447

Review 5.  Drug metabolism alterations in nonalcoholic fatty liver disease.

Authors:  Matthew D Merrell; Nathan J Cherrington
Journal:  Drug Metab Rev       Date:  2011-05-25       Impact factor: 4.518

Review 6.  Drug disposition in pathophysiological conditions.

Authors:  Adarsh Gandhi; Bhagavatula Moorthy; Romi Ghose
Journal:  Curr Drug Metab       Date:  2012-11       Impact factor: 3.731

7.  Sources of Interindividual Variability.

Authors:  Yvonne S Lin; Kenneth E Thummel; Brice D Thompson; Rheem A Totah; Christi W Cho
Journal:  Methods Mol Biol       Date:  2021

Review 8.  Liver 'organ on a chip'.

Authors:  Colin H Beckwitt; Amanda M Clark; Sarah Wheeler; D Lansing Taylor; Donna B Stolz; Linda Griffith; Alan Wells
Journal:  Exp Cell Res       Date:  2017-12-29       Impact factor: 3.905

9.  Editor's Highlight: Mechanistic Toxicity Tests Based on an Adverse Outcome Pathway Network for Hepatic Steatosis.

Authors:  Michelle M Angrish; Charlene A McQueen; Elaine Cohen-Hubal; Maribel Bruno; Yue Ge; Brian N Chorley
Journal:  Toxicol Sci       Date:  2017-09-01       Impact factor: 4.849

10.  A cellular model to study drug-induced liver injury in nonalcoholic fatty liver disease: Application to acetaminophen.

Authors:  Anaïs Michaut; Dounia Le Guillou; Caroline Moreau; Simon Bucher; Mitchell R McGill; Sophie Martinais; Thomas Gicquel; Isabelle Morel; Marie-Anne Robin; Hartmut Jaeschke; Bernard Fromenty
Journal:  Toxicol Appl Pharmacol       Date:  2015-12-29       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.